Propafenone and Its Metabolites Preferentially Inhibit IKr in Rabbit Ventricular Myocytes

Journal of Pharmacology and Experimental Therapeutics

Volumn 308, Issue 1, 2004, Pages 59-65

  Cahill, Sean A ^a   Gross, Gil J ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYPROPAFENONE; ANTIARRHYTHMIC AGENT; DEPROPYLPROPAFENONE; DRUG METABOLITE; PROPAFENONE;

ANIMAL CELL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTRIC POTENTIAL; ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART VENTRICLE; IC 50; MALE; MODEL; NONHUMAN; PATCH CLAMP; PEAK TAIL CURRENT AMPLITUDE; PHARMACOLOGICAL BLOCKING; POTASSIUM CURRENT; PRIORITY JOURNAL; PROARRHYTHMIC ACTIVITY; RABBIT; REPOLARIZATION; TRANSIENT OUTWARD POTASSIUM CURRENT; ULTRARAPIDLY ACTIVATING DELAYED RECTIFIER POTASSIUM CURRENT; VOLTAGE DEPENDENCE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; HEART VENTRICLES; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; POTASSIUM CHANNELS; PROPAFENONE; RABBITS;

EID: 0347128183     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.057844     Document Type: Article

References (39)

1. Boucher M, Chassaing C, Hamel JD, and Poirier JM (1996) Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog. Eur J Pharmacol 315:171-177.
2. Cahill SA, Kirshenbaum LA, and Gross GJ (2001) Transient outward current inhibition by propafenone and 5-hydroxypropafenone in cultured neonatal rat ventricular myocytes. J Cardiovasc Pharmacol 38:460-467.
3. Camm AJ, Janse MJ, Roden DM, Rosen MR, Cinca J, and Cobbe SM (2000) Congenital and acquired long QT syndrome. Eur Heart J 21:1232-1237.
4. + current in cardiac myocytes by dofetilide. J Pharmacol Exp Ther 262:809-817.
5. + currents in cardiac cells: comparison with terfenadine. Br J Pharmacol 124:663-668.
6. Case CL, Ravin RR, Maheshwari R, Gillette PC, and Hewett KW (1991) Developmental electrophysiologic effects of propafenone and 5-hydroxypropafenone on the canine cardiac Purkinje fiber. Dev Pharmacol Ther 17:24-34.
7. + channels in rabbit atrial and ventricular cardiomyocytes. Eur J Pharmacol 373:223-232.
8. Delgado C, Tamargo J, Tejerina T, and Valenzuela C (1987) Effects of 5-hydroxypropafenone in guinea-pig atrial fibres. Br J Pharmacol 90:575-582.
9. + current in guinea pig ventricular myocytes. Voltage-independent and time-dependent block of the slowly activating component. Circ Res 76:223-235.
10. Duan D, Fermini B, and Nattel S (1993) Potassium channel blocking properties of propafenone in rabbit atrial myocytes. J Pharmacol Exp Ther 264:1113-1123.
11. K, by flecainide and E-4031 in cat ventricular myocytes. Circulation 82:289-293.
12. Franqueza L, Valenzuela C, Delpon E, Longobardo M, Caballero R, and Tamargo J (1998) Effects of propafenone and 5-hydroxy-propafenone on hKv1.5 channels. Br J Pharmacol 125:969-978.
13. Grant AO (1996) Propafenone: an effective agent for the management of supraventricular arrhythmias. J Cardiovasc Electrophysiol 7:353-364.
14. Gross GJ, Burke RP, and Castle NA (1995) Characterisation of transient outward current in young human atrial myocytes. Cardiovasc Res 29:112-117.
15. Gross GJ and Castle NA (1998) Propafenone inhibition of human atrial myocyte repolarizing currents. J Mol Cell Cardiol 30:783-793.
16. Haefeli WE, Vozeh S, Ha HR, Taeschner W, and Follath F (1991) Concentration-effect relations of 5-hydroxypropafenone in normal subjects. Am J Cardiol 67:1022-1026.
17. Hamill OP, Marty A, Neher E, Sakmann B, and Sigworth FJ (1981) Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflueg Arch 391:85-100.
18. 2H-labelled propafenone in man. Eur J Drug Metab Pharmacokinet 9:41-55.
19. Kates RE, Yee YG, and Winkle RA (1985) Metabolite cumulation during chronic propafenone dosing in arrhythmia. Clin Pharmacol Ther 37:610-614.
20. Kääb S, Dixon J, Duc J, Ashen D, Näbauer M, Beuckelmann DJ, Steinbeck G, McKinnon D, and Tomaselli GF (1998) Molecular basis of transient outward potassium current downregulation in human heart failure: a decrease in Kv4.3 mRNA correlates with a reduction in current density. Circulation 98:1383-1393.
21. Latini R, Barbieri E, Castello C, Marchi S, Sica A, Gerosa G, Rossi R, and Zardini P (1989) Propafenone and 5-hydroxypropafenone concentrations in the right atrium of patients undergoing heart surgery. Am Heart J 117:497-498.
22. Latini R, Marchi S, Riva E, Cavalli A, Cazzaniga MG, Maggioni AP, and Volpi A (1987) Distribution of propafenone and its active metabolite, 5-hydroxypropafenone, in human tissues. Am Heart J 113:843-844.
23. c and action potential duration. Br J Pharmacol 132:101-110.
24. Malfatto G, Zaza A, Forster M, Sodowick B, Danilo PJ, and Rosen MR (1988) Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J Pharmacol Exp Ther 246:419-426.
25. Mergenthaler J, Haverkamp W, Huttenhofer A, Skryabin BV, Musshoff U, Borggrefe M, Speckmann EJ, Breithardt G, and Madeja M (2001) Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn-Schmiedeberg's Arch Pharmacol 363:472-480.
26. Paul AA, Witchel HJ, and Hancox JC (2002) Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136:717-729.
27. Paul T and Janousek J (1994) New antiarrhythmic drugs in pediatric use: propafenone. Pediatr Cardiol 15:190-197.
28. Rolf S, Haverkamp W, Borggrefe M, Musshoff U, Eckardt L, Mergenthaler J, Snyders DJ, Pongs O, Speckmann EJ, Breithardt G, et al. (2000) Effects of antiarrhythmic drugs on cloned cardiac voltage-gated potassium channels expressed in Xenopus oocytes. Naunyn-Schmiedeberg's Arch Pharmacol 362:22-31.
29. Rouet R, Libersa CC, Broly F, Caron JF, Adamantidis MM, Honore E, Wajman A, and Dupuis BA (1989) Comparative electrophysiological effects of propafenone, 5-hydroxy- propafenone and N-depropylpropafenone on guinea pig ventricular muscle fibers. J Cardiovasc Pharmacol 14:577-584.
30. Ks. Am J Physiol 271:H2477-H2489.
31. Kr potassium channel. Cell 81:299-307.
32. Seki A, Hagiwara N, and Kasanuki H (1999) Effects of propafenone on K currents in human atrial myocytes. Br J Pharmacol 126:1153-1162.
33. Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, and Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75:785-791.
34. + channel blocking actions of flecainide compared with those of propafenone and quinidine in adult rat ventricular myocytes. J Pharmacol Exp Ther 269:66-74.
35. Thompson KA, Iansmith DH, Siddoway LA, Woosley RL, and Roden DM (1988) Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. J Pharmacol Exp Ther 244:950-955.
36. Valenzuela C, Delgado C, and Tamargo J (1987) Electrophysiological effects of 5-hydroxypropafenone on guinea pig ventricular muscle fibers. J Cardiovasc Pharmacol 10:523-529.
37. Valenzuela C, Delpon E, and Tamargo J (1988) Tonic and phasic Vmax block induced by 5-hydroxypropafenone in guinea pig ventricular muscles. J Cardiovasc Pharmacol 12:423-431.
38. von Philipsborn G, Gries J, Hofmann HP, Kreiskott H, Kretzschmar R, Muller CD, Raschack M, and Teschendorf HJ (1984) Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone. Arzneim-Forsch 34:1489-1497.
39. 2+ on Kv4.2 and Kv1.4 expressed in Xenopus oocytes and on the transient outward currents in rat and rabbit ventricular myocytes. Cell Physiol Biochem 9:11-28.